Wall Street analyst estimates for Fate Therapeutics, Inc. (FATE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 13 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 31 |
| Avg rating (1-5) | 0.45 |
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | -2.84 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $4.7M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Cost of Revenue | $26.5M | $34.4M | $56.0M | 0 | $125.6M | $5.8M | $13.8M | $157.2M | $118.5M | $12.9M |
| Gross Profit | -$22.1M | -$30.3M | -$51.3M | $10.7M | -$94.2M | $50.0M | $82.5M | -$93.7M | -$104.9M | -$6.3M |
| Research & Development | $26.5M | $34.4M | $56.0M | $87.8M | $125.6M | $215.5M | $320.5M | $172.6M | $135.0M | $107.8M |
| Selling, General & Admin | $9.9M | $11.9M | $15.8M | $23.6M | $33.9M | $57.3M | $84.2M | $96.9M | $90.6M | $46.5M |
| Operating Expenses | $36.4M | $46.2M | $71.8M | $111.4M | $33.9M | $267.0M | $390.9M | $96.9M | $105.4M | $141.4M |
| Operating Income | -$32.0M | -$42.1M | -$67.1M | -$100.7M | -$128.1M | -$217.0M | -$308.4M | -$190.5M | -$210.3M | -$147.7M |
| EBITDA | -$30.9M | -$40.7M | -$63.7M | -$94.2M | -$125.0M | -$206.3M | -$268.0M | -$142.6M | -$176.6M | -$127.0M |
| Interest Expense | $1.6M | $1.3M | $1.7M | $1.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$33.5M | -$43.0M | -$66.6M | -$98.1M | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| Income Tax | 0 | $297000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$33.5M | -$43.0M | -$66.6M | -$98.1M | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| EPS | $-1.05 | $-1.02 | $-1.19 | $-1.43 | $-2.10 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | $-1.15 |
| EPS (Diluted) | $-1.05 | $-1.02 | $-1.19 | $-1.43 | $-2.10 | $-2.24 | $-2.91 | $-1.64 | $-1.64 | $-1.15 |
| Shares Outstanding (Diluted) | $31.8M | $42.0M | $56.2M | $68.2M | $82.4M | $94.7M | $96.8M | $98.4M | $113.7M | $118.8M |
Price
| Price | $2.44 |
| Market Cap | $284M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of FATE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks